



ROODMAN, G. DAVID Professor of Medicine; Vice Chair for Medicine Research; Director, Myeloma Program; Director, Center for Bone Biology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Place of Birth: Louisville, Kentucky, USA

Education/Training/Positions: BA, The Johns Hopkins University, Baltimore, Maryland, 1969; MD, University of Kentucky College of Medicine, Lexington, Kentucky, 1973; PhD, University of Kentucky, 1975; Intern in Medicine, University of Kentucky, 1975-1976; Resident in Medicine, University of Minnesota, Minneapolis, MN, 1976-1978; Fellow in Hematology, University of Minnesota, 1978-1980; Research Associate, University of Minnesota, 1978-1980; Assistant Professor, Associate Professor, Professor of Medicine, and Associate Chair for Research, University of Texas Health Science Center at San Antonio (UTHSCSA), Texas, 1980-2001; Staff Physician, Director of Hematology Clinic, and Chief of Hematology Section, Audie Murphy Veterans Administration Hospital, San Antonio, Texas, 1981-2001; Associate Scientist, Biomedical Research Foundation of South Texas, 1986-2001; Director, Bone Biology Center, University of Pittsburgh Medical Center, Pittsburgh, PA, 2001-present; Director, Myeloma Program, University of Pittsburgh Cancer Institute, 2001-present; Professor of Medicine, University of Pittsburgh School of Medicine, 2001-present; Vice Chair for Research, Department of Medicine, University of Pittsburgh School of Medicine, 2002-present

Honors/Awards: Delta Phi Alpha, 1969; Clinical Investigator, Veterans Administration, 1988-1993; The Paget Foundation Research Award, 1989; American Society for Clinical Investigation, 1991; The Paget Foundation Research Award, 1993; Association of American Physicians, 1996; Dr. Bernard G. and Rhoda Sarnat Lectureship in Bone Biology for Contribution to Advancement of Science in the State of Israel, 2000; The Paget Foundation Research Award, 2002; John B. Johnson Award for Research in Paget's Disease, 2002; Pittsburgh Magazine "Top Doctor" list, 2005-2009; Louis V. Avioli Founders Award for Basic Research in Bone, 2007

Editorial Duties/Peer Review Panels: Editorial Boards: *Experimental Hematology*, 1991-present; *Bone*, 1993-present; *Journal of Clinical Investigation*, 1998-present; *Endocrinology*, 2001-present; *Experimental Biology and Medicine*, 2006-present; Associate Editor, *Journal of Bone and Mineral Research*, 2002-2008; Review Panels: American Heart Association Grant Reviewer, 1984-1989; VA Merit Review Board-Hematology, 1987-1990; National Osteoporosis Foundation Grant Reviewer, 1987-present; Ad Hoc Reviewer, NIH, Oral Biology and Study Section, 1991-1993; Osteoclast Abstract Reviewer, ASBMR 2000-present; International Myeloma Foundation Grant Reviewer, 2001-Present; The Israel Science Foundation (ISF) Grant Reviewer, 2002; Multiple Myeloma Research Foundation (MMRF) Grant Reviewer, 2004-present; NIH, Program Project Reviewer, 2005; USAMRMC Bone Health & Military Medical Readiness Report Reviewer, 2005; New England Journal of Medicine Textbook Reviewer, 2005; SRA, Skeletal Biology Structure & Regeneration Study Section, 2005-present; VA Research Scientific Evaluation Committee 2009

Professional Societies: Memberships: American Society of Hematology, 1980-present; International Society for Experimental Hematology, 1982-present; American Association for the Advancement of Science, 1983-present; American Society for Bone and Mineral Research, 1984-present; Council of the American Federation for Clinical Research, 1986-1989; American Society for Clinical Investigation, 1990-present; International Bone and Mineral Society, 1991-present; Association of American Physicians, 1996-present; The Endocrine Society, 2002-present; American Society for Biochemistry and Molecular Biology, 2006-present; Counselor, Southern Society for Clinical Investigation, 1993-1998; Nominating Committee, ASBMR, 1994-1995; Nominating Committee, Int'l Society for Experimental Hematology, 1995-1998; Advocacy Committee, ASBMR, 1999-2004; Paget's Foundation Board Member, 2001-2004; MMRF Scientific Advisory Board Member, 2001-2004; Advisory Council of the NIH Osteoporosis and Related Bone Diseases, 2001-present; Scientific Advisory Board of the International Myeloma Foundation, 2001-present; Scientific Program Committee, ASBMR, 2002; Member, International Bone and Mineral Society Publications Committee, 2002-present; Strategic Advisor, Scios Inc., Developing Myeloma Therapeutics and Innovative Therapies, 2003; Consultant, NIH, Osteoporosis and Related Bone Disease, National Resource Center, 2003; Co-Chair, National Cancer Institute's "Think Tank," The Tumor Microenvironment, 2003; Chairman for the Paget Foundation, 2006-present; Member of the ASH Ad Hoc Scientific Committee on Plasma Cell Biology, 2007-present

Current Research: Focuses on the role of osteoclasts in normal and pathologic conditions such as Paget's disease and multiple myeloma. We are evaluating the potential utility of blocking ADAM8 and $\alpha_v\beta_1$ integrin, as therapeutic targets for decreasing the bone destruction in rheumatoid arthritis and the contribution of osteoclasts in stimulating angiogenesis in myeloma and solid tumor bone metastases. In addition, we have developed in vivo models of Paget's disease to determine the contribution of environmental and genetic factors to the development of Paget's disease. Most recently, we demonstrated that GFI-1 is responsible in part for osteoblast suppression in myeloma and are now determining if blocking GFI-1 expression reverses bone destruction and osteoblast suppression in myeloma models.

Statement of Interest: I am very interested in becoming a councilor for the ASBMR because I want to continue my active involvement in the society and keep the ASBMR as the outstanding society for bone research. I have been involved in the ASBMR since 1981 when I attended the ASBMR meeting in San Antonio. Since that time, I have participated as an abstract

reviewer on multiple occasions, was on the Advocacy Committee for 5 years, served as an Associate Editor for the Journal of Bone and Mineral Research, and participated at the new investigator meetings and symposia such as AIMM. Through the efforts of the Journal of Bone and Mineral Research and ASBMR, the importance of bone research has become appreciated by scientists and laymen outside of the bone field, as evidenced by the increasing numbers of bone related presentations at the American Society of Hematology and the American Society of Clinical Oncology, societies that were previously unaware of or did not highlight the importance of bone research. One of the most important functions of the ASBMR is to mentor young investigators; and as councilor, I plan to continue to promote the AIMM Meeting, which I think is a very important forum for young investigators to present and network with established investigators, and to develop new initiatives that further enhance young investigators' research. Young investigators have to be made aware of other sources of funding outside of the NIH in order to maintain their laboratories until the current funding climate changes. Without these types of activities, the ranks of the next generation of bone researchers will be severely depleted. In addition, I think that it is very important that the society foster interactions with other societies beyond the bone field. In particular, the rheumatologic societies and the cancer societies are all important interactions that need to be pursued and enhanced. Equally important are the advocacy activities of the ASBMR, which have to be continued and strengthened to help both established and young investigators obtain grant support in this highly competitive era of NIH funding as well as to make the public more aware of bone health issues. Continuing to bring outstanding investigators from outside the bone field to the ASBMR meeting is yet another important area that must be maintained. State-of-the-art symposia highlighting cutting-edge technologies and discoveries have become a feature of the ASBMR annual meeting. Developing seminars on how these discoveries can be adapted to the bone field is an important goal for the continued progress in bone research. I hope to continue to increase these programs. Finally, to continue ASBMR as an international society, I would work to strengthen our interactions with bone researchers/societies in other parts of the world including Eastern Europe and South America and hold joint meetings and co-sponsor meetings focused on important areas in bone research

Disclosures: Novartis Pharmaceuticals 1, 2, 3; Amgen 2; Celgene 2; Acceleron 2; Millennium 2

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*